TissueGene commences patient recruitment in DJD drug Phase II trial
TissueGene expects to recruit around 100 patients in the trial across US. In the Phase II trial, the patients will be given intra-articular injection of either TG-C or
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.